Home › Research › Biomarkers
Neuroprotective role of Origanum majorana essential oil loaded in mixed surfactants based nano emulsion against lipopolysaccharide-induced Alzheimer in mice
Abeer Salama, Rasha M.M. Mohasib, Eman Samy Shalaby. Journal of Pharmaceutical Investigation, 2025-03-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Abstract Purpose The current study aims to improve the oral bioavailability of Origanum majorana essential oil loaded nanoemulsions (OMEO -NEs) for the treatment of Alzheimer’s disease in mice induced by lipopolysaccharide (LPS). Methods Gas Chromatography–Mass Spectrometry analysis (GC–MS) analyses were performed to determine the Origanum majorana leaves essential components. Yield essential oil, phenolic content, and flavonoid content were also ascertained. Four NEs containing various concentrations of carboxy methyl cellulose (CMC) and a fixed concentration of Tween 80 as mixed emulsifiers. Plain OMEO and its chosen NE were tested for their antioxidant properties against DPPH & ABTS, hydrogen peroxide, and metal chelation assay. The mice in the in vivo study were divided into five groups at random (8 per group): Group 1: normal control group. Group 2: LPS positive group (250 µg/kg; intraperitoneal); Groups 3–5: Oral administration of 400 mg/kg of Blank NE, plain OMEO, and OMEO-NE for 7 days in conjunction with LPS. Results GC–MS identified the primary constituents which are α-Terpineol (21.85%), γ-Terpinene (12.43), and α-Caryophyllene (11.78%). The encapsulation efficiency % of NE was improved when the concentration of CMC was reduced. Particle size and zeta potential values in the prepared NE were reasonable. In every test, the chosen OMEO-NE showed stronger antioxidant activity than plain OMEO. When compared to LPS-treated mice, OMEO-NE increased cognitive function and decreased AChE, TLR4, and GFAP levels. Conclusion The current study provides opportunities for safer approaches that using compounds derived from plants and links it to nanotechnology, could be used in the pharmaceutical industry to treat Alzheimer’s disease.
What this study adds
Evidence grade: Low
In mice with lipopolysaccharide-induced Alzheimer-like changes, a nanoemulsion of Origanum majorana essential oil improved cognitive function and lowered AChE, TLR4 and GFAP levels compared with untreated mice. Reported effect size: 21.85%; 11.78%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Salama, A., Mohasib, R. M., & Shalaby, E. S. (2025). Neuroprotective role of Origanum majorana essential oil loaded in mixed surfactants based nano emulsion against lipopolysaccharide-induced Alzheimer in mice. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-024-00696-5
Vancouver
Salama A, Mohasib RM, Shalaby ES. Neuroprotective role of Origanum majorana essential oil loaded in mixed surfactants based nano emulsion against lipopolysaccharide-induced Alzheimer in mice. Journal of Pharmaceutical Investigation. 2025. doi:10.1007/s40005-024-00696-5.
BibTeX
@article{salama2025-ba0980c1,
author = {Salama, Abeer and Mohasib, Rasha M.M. and Shalaby, Eman Samy},
title = {{Neuroprotective role of Origanum majorana essential oil loaded in mixed surfactants based nano emulsion against lipopolysaccharide-induced Alzheimer in mice}},
journal = {Journal of Pharmaceutical Investigation},
year = {2025},
doi = {10.1007/s40005-024-00696-5},
url = {https://doi.org/10.1007/s40005-024-00696-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results GC–MS identified the primary constituents which are α-Terpineol (21.85%), γ-Terpinene (12.43), and α-Caryophyllene (11.78%).
- When compared to LPS-treated mice, OMEO-NE increased cognitive function and decreased AChE, TLR4, and GFAP levels.
Why it matters
In mice with lipopolysaccharide-induced Alzheimer-like changes, a nanoemulsion of Origanum majorana essential oil improved cognitive function and lowered AChE, TLR4 and GFAP levels compared with untreated mice. This is an animal study only, so it does not show any benefit for people with Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size21.85%; 11.78%
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Pharmaceutical Investigation) |
| Journal's citation record | 0 / 4 | Journal of Pharmaceutical Investigation: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mice”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Eman Samy Shalaby: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | National Research Centre: institution h-index 279 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s40005-024-00696-5
- Original source →
- Free full text: Journal of Pharmaceutical Investigation →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.